


What is claimed is:

1. A combination for simultaneous, separate or sequential use which comprises (a) a cyclin-dependent kinase inhibitor and (b) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide having the formula I



(I)

- in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier.
2. A combination for simultaneous, separate or sequential use which comprises (a) a cyclin-dependent kinase inhibitor and (b) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide having the formula I in which the active ingredients (a) and (b) are present in a synergistically effective amount in each case in free form or in the form of a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier.
3. Use of a combination according to claim 1 or 2 in the treatment of a tumor disease.
4. Use of a combination according to any one of claims 1 or 2 for the preparation of a medicament in the treatment of a tumor disease.
5. Use of a combination according to claim 3 or 4 wherein the tumor disease is leukemia.
6. Use of a combination according to any one of claim 5 wherein the leukemia is a Bcr/Abl-positive leukemia.

7. Use of a combination according to claim 6 wherein the Bcr/Abl-positive leukemia is a compound of formula I-resistant leukemia.
8. Use of a combination according to claim 7 wherein the Bcr/Abl-positive leukemia resistant to compound of formula I over-expresses Bcr/Abl.
9. Use or combination according to any one of claims 1 to 8 wherein the cyclin-dependent kinase inhibitor is selected from the group consisting of purine-based derivatives, pyridimine-based derivatives, benzenesulfonamides, flavonoids, thiazole derivatives, paullone derivatives, staurosporine derivatives, indigoid bisindoles, butyrolactone 1, pyrazolopyridine compounds, indol derivatives and amino-pyrazole compounds.
10. Use or combination according to any one of claims 1 to 9 wherein the cyclin-dependent kinase inhibitor is flavopiridol or E 7070 or CYC 202.
11. Use or combination according to any one of claims 1 to 10 wherein the cyclin-dependent kinase inhibitor is flavopiridol.
12. Use or combination according to claim 11 wherein flavopiridol and 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide are present in a synergistically effective molar ratio (FP/COMPOUND I) range of 1:1 to 1:10.
13. A method of treating a warm-blooded animal having a proliferative disease comprising administering to the animal a combination according to any one of claims 1 to 12 in a quantity which is jointly therapeutically effective against said proliferative disease and in which the compounds can also be present in the form of their pharmaceutically acceptable salts.
14. A method of inhibiting the formation of metastases in a warm-blooded animal having a tumor disease which comprises administering to the patient a pharmaceutically effective amount of a combination according to any one of claims 1 to 13 in a quantity which is jointly therapeutically effective against said tumor disease and in which the compounds can also be present in the form of their pharmaceutically acceptable salts.

15. A pharmaceutical composition comprising a quantity which is jointly therapeutically effective against a tumor disease of a pharmaceutical combination according to claim 1 to 12 and at least one pharmaceutically acceptable carrier.
16. A commercial package comprising a combination according to any one of claims 1 to 12 together with instructions for simultaneous, separate or sequential use thereof in the treatment of a proliferative disease.